Loading market movers...

Nemolizumab 30 mg

Phase 3

Galderma Group AG/ADR (GALDY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Prurigo Nodularis

INCYVehicle Cream

VYNEserlopitant

View Full Landscape

Drug Information

Target Indication

Prurigo Nodularis

Clinical Trial

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/12/2025

Nemluvio

Atopic dermatitis (AD) Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Prurigo nodularis (PN) Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

Drug Science

Mechanism of action & safety profile

Developer

GALDY

Galderma Group AG/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

MAL 16.8% creamPhase 3

Actinic Keratoses

Adapalene BPO Gel standard daily overnight applicationPhase 3

Acne

botulinum toxin neuromodulatorPhase 3

Glabellar Lines

Metvix and natural daylight PDTPhase 3

Actinic Keratoses

OnabotulinumtoxinAPhase 3

Moderate to Severe Glabellar Lines

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts